<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366546</url>
  </required_header>
  <id_info>
    <org_study_id>1301-01</org_study_id>
    <nct_id>NCT02366546</nct_id>
  </id_info>
  <brief_title>Investigator Initiated Phase 1 Study of TBI-1301</brief_title>
  <official_title>Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takara Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fiverings Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statcom Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene
      transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following pre-treatment with cyclophosphamide alone or in combination with fludarabine,
      NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to HLA-A*02:01 or
      HLA-A*02:06 positive patients with solid tumors which are 1) unresectable, refractory to
      standard therapy (chemotherapy, radiotherapy, etc), and 2) NY-ESO-1-expressing. The primary
      objective is to evaluate the safety and in vivo kinetics, and the secondary is to evaluate
      clinical effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and grade of adverse events (CTCAE)</measure>
    <time_frame>4 weeks</time_frame>
    <description>• Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance of replication competent retrovirus by PCR</measure>
    <time_frame>4 weeks</time_frame>
    <description>Confirm no replication competent retrovirus observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance of clonality by LAM-PCR</measure>
    <time_frame>4 weeks</time_frame>
    <description>Confirm no clonality is observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kinetics of TBI-1301 in blood by realtime-PCR</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluate persistence and expansion of transferred TBI-1301.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Low dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose TBI-1301 with pre-treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBI-1301 with pre-treatment 1 or 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm1, 2 or 3, which is considered as optimal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBI-1301</intervention_name>
    <description>TBI-1301(5*10^8 or 5*10^9) is administered.</description>
    <arm_group_label>Low dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_label>High dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_label>High dose TBI-1301 with pre-treatment 2</arm_group_label>
    <arm_group_label>TBI-1301 with pre-treatment 1 or 2</arm_group_label>
    <other_name>NY-ESO-1-specific TCR gene transduced T lymphocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.</description>
    <arm_group_label>Low dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_label>High dose TBI-1301 with pre-treatment 1</arm_group_label>
    <arm_group_label>High dose TBI-1301 with pre-treatment 2</arm_group_label>
    <arm_group_label>TBI-1301 with pre-treatment 1 or 2</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.</description>
    <arm_group_label>High dose TBI-1301 with pre-treatment 2</arm_group_label>
    <arm_group_label>TBI-1301 with pre-treatment 1 or 2</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed solid tumors

          2. Solid tumor, which is unresectable, refractory to standard therapy (chemotherapy,
             radiotherapy, etc)

          3. HLA-A*02:01 or HLA-A*02:06 positive

          4. NY-ESO-1-expression by PCR or immunohistochemistry

          5. ECOG Performance Status, 0 or 1

          6. Age &gt;=20 years on consent

          7. No treatment (surgery, chemotherapy, radiotherapy, etc.) and expected sufficient
             recovery from the treatment at the time of the lymphocytes collection for gene
             transfer.

          8. Life expectancy &gt;=16 weeks after consent

          9. No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc)
             and meet the following lab value criteria:

               -  WBC &gt;= 2,500/μL

               -  Hemoglobin &gt;= 8.0g/dL

               -  Platelets &gt;= 75,000/μL

               -  T. bilirubin &lt; 1.5 x ULN

               -  AST(GOT), ALT(GPT) &lt; 3.0 x ULN

               -  Creatinine &lt; 1.5 x ULN

         10. Ability to understand the study contents and to give a written consent at his/her free
             will.

        Exclusion Criteria:

          1. The following serious complications are excluded from the study;

               -  Unstable angina, cardiac infarction, or heart failure

               -  Uncontrolled diabetes or hypertension

               -  Active infection

               -  Obvious interstitial pneumonia or lung fibrosis by chest X-ray

               -  Active autoimmune disease requiring steroids or immunosuppressive therapy.

          2. Serious hypersensitivity

          3. Tumor cell invasion into CNS

          4. Active multiple cancer

          5. Positive for HBs antigen or HBV-DNA observed in serum

          6. Positive for HCV antibody and HCV-RNA observed in serum

          7. Positive for antibodies against HIV or HTLV-1

          8. Left Ventricular Ejection Fraction (LVEF): &lt;= 50％

          9. Percutaneous Oxygen saturation: &lt; 94％

         10. History of serious hypersensitivity reactions to bovine or murine derived substances.

         11. History of hypersensitivity reaction to drugs used in this study.

         12. Psychological disorder or drug dependency which may have impact on the consent.

         13. Pregnant females, lactating females (except when they cease and don't resume
             lactation) or female and male patients who cannot agree to practice the adequate birth
             control after the consent during the study

         14. Clinically significant systemic illness that in the judgment of the PI or
             sub-investigator would compromise the patient's ability to tolerate protocol therapy
             or significantly increase the risk of complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Shiku, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Immuno-Gene Therapy, Mie University, Graduate School of Medicine Mie University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shinichi Kageyama, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Immuno-Gene Therapy, Mie University, Graduate School of Medicine Mie University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroshi Miyamoto</last_name>
    <phone>+81-6-6358-7004</phone>
    <email>miyamoto@fiverings.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuyuki Ota, Ph.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Chisato Minamide, RN</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mie University</investigator_affiliation>
    <investigator_full_name>Shinichi Kageyama</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adoptive cell transfer</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>NY-ESO-1</keyword>
  <keyword>Esophageal cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Synovial sarcoma</keyword>
  <keyword>TCR gene therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

